NCT02185066View on ClinicalTrials.gov

Phase 1 Study to Compare the Safety, Pharmacokinetic Profiles of CJ-30056 and Lipitor/Glucophage XR

PHASE1CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

September 30, 2014

Study Completion Date

November 30, 2014

Conditions
Healthy Volunteers
Interventions
DRUG

Atorvastatin 20mg and Metformin XR 500mg (Reference)

"Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between."

DRUG

CJ-30056 20/500mg (Test)

"Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.~Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between."

Trial Locations (1)

Unknown

Inje University Busan Paik Hospital, Busan

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY